

Special Issue

Personalized Medicine of Human Mpox Virus Infections

Message from the Guest Editor

The global mpox (formerly monkeypox) outbreaks during 2022–2023 highlighted the critical role of personalized approaches in infectious disease control. Originally identified in Central Africa, mpox has expanded globally, with recent outbreaks in Western countries swiftly contained through targeted vaccination, risk-based interventions, and individualized public health strategies.

This Special Issue invites research focused on mpox within the framework of personalized medicine. Topics of interest include the following: omics-based studies of disease susceptibility and therapeutic response; biomarker discovery; pharmacogenomics of vaccine and antiviral responses; and applications of bioinformatics, artificial intelligence, and machine learning. We also encourage submissions on novel therapeutics and molecular diagnostics tailored to individual risk profiles.

Through integrating omics technologies, personalized therapeutics, and responsible public health frameworks, this Special Issue aims to advance mpox management as a model for future emerging infections.

Guest Editor

Dr. David Jesse Sanchez

College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA

Deadline for manuscript submissions

31 March 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/242382

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).